GAITHERSBURG, Md.,
Aug. 12, 2020 /PRNewswire/ -- GeneDx, Inc., a subsidiary
of BioReference Laboratories, Inc., an OPKO Health company
(NASDAQ:OPK), the global leader in neonatal and pediatric
genetic testing, announced the entrance into an agreement with
Pediatrix Medical Group ("Pediatrix"), the nation's leading
provider of maternal-fetal, and pediatric medical and surgical
subspecialty physician services, to offer state-of-the-art,
next-generation genomic sequencing to support clinical diagnosis in
neonatal intensive care units ("NICUs") staffed by Pediatrix's
affiliated neonatologists. The sequencing is designed to enhance
diagnostic capabilities in order to lessen the impact of disease
and facilitate the development of novel precision medicine
solutions for pediatric care. The initial offering will
include whole exome and whole genome sequencing and genomic support
services under the brand Detect Genomix and the initial clinical
diagnostic support services will be made available to hospitals and
patients across the country.
"Our innovative technology, advanced analytics, customized
genomic reports and genetic counseling offerings coupled with
Pediatrix's vast neonatal clinical experience and expansive
coverage across the country set the stage for this arrangement to
provide the first comprehensive offering of this type to hospitals
and health systems nationwide," said Jon R.
Cohen, M.D., Executive Chairman of BioReference Laboratories
and GeneDx.
"Our combined network of more than 2,200 affiliated physicians
and GeneDx's more than 100 genetic counselors will make Detect
Genomix one of the nation's largest neonatal genomics platforms,"
said Ingrid Vasiliu-Feltes, M.D.,
MBA, Chief Quality and Innovation Officer at Pediatrix. "Genetic
disorders and congenital anomalies are a leading cause of neonatal
morbidity and mortality, and time to diagnosis is a crucial factor
in the treatment of the patient. This arrangement is designed to
provide Pediatrix-affiliated neonatologists with access to the
latest sequencing technology."
About GeneDx, Inc.
GeneDx, Inc. is a global leader in genomics, providing testing
to patients and their families from more than 55 countries. Led by
its world-renowned clinical genomics program, GeneDx has an
acknowledged expertise in rare and ultra-rare genetic disorders, as
well as one of the broadest menus of sequencing services available
among commercial laboratories. GeneDx offers a suite of additional
genetic testing services, including diagnostic testing for
hereditary cancers, cardiac, mitochondrial, neurological disorders,
prenatal diagnostics and targeted variant testing. GeneDx is a
subsidiary of BioReference Laboratories, Inc., a wholly owned
subsidiary of OPKO Health, Inc. To learn more, please visit
www.genedx.com.
About OPKO Health, Inc.
OPKO is a multinational biopharmaceutical and diagnostics
company that seeks to establish industry-leading positions in
large, rapidly growing markets by leveraging its discovery,
development, and commercialization expertise and novel and
proprietary technologies. For more information, visit
www.opko.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking statements," as
that term is defined under the Private Securities Litigation Reform
Act of 1995 (PSLRA), which statements may be identified by words
such as "expects," "plans," "projects," "will,"
"may," "anticipates," "believes," "should," "intends," "estimates,"
and other words of similar meaning, including statements regarding
the strengths and resources of GeneDx and its counterparty, the
role and value of genomic sequencing and whether such sequencing
will significantly enhance diagnostic capabilities or lessen the
impact of disease or facilitate the development of novel precision
medicine solutions for pediatric care; rapid whole exome and genome
sequencing in neonatal intensive care units; statements about the
experience and technology of each of GeneDx and
its counterparty; statements about the uniqueness of the proposed
offerings of Detect Genomix; as well as other non-historical
statements about our expectations, beliefs or intentions regarding
our business, technologies and products, financial condition,
strategies or prospects. Many factors could cause our actual
activities or results to differ materially from the activities and
results anticipated in forward-looking statements. These factors
include those described in the OPKO Health, Inc. Annual Reports on
Form 10-K filed and to be filed with the Securities and Exchange
Commission and in its other filings with the Securities and
Exchange Commission. In addition, forward-looking statements may
also be adversely affected by general market factors, competitive
product and service development, federal and state regulations and
legislation, and the regulatory process for testing and services,
among other factors. The forward-looking statements contained in
this press release speak only as of the date the statements were
made, and we do not undertake any obligation to update
forward-looking statements. We intend that all forward-looking
statements be subject to the safe-harbor provisions of the
PSLRA.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/opko-healths-genedx-enters-into-agreement-with-pediatrix-medical-group-to-offer-neonatal-genomic-services-301110912.html
SOURCE GeneDx, Inc.